From the MD/PhD Program, Vanderbilt University School of Medicine, Nashville, TN (J.K.); Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia (J.K., S.H.-S., C.A.B., M.A.A., P.A., C.R.B.); and The Ohio State University, Columbus (P.K., P.I.M.).
Circ Res. 2017 Sep 29;121(8):963-969. doi: 10.1161/CIRCRESAHA.117.310848. Epub 2017 Jul 20.
The objective of this autopsy study was to determine whether gastrointestinal angiodysplasia develops during continuous-flow left ventricular assist device (LVAD) support.
LVAD support causes pathologic degradation of von Willebrand factor (vWF) and bleeding from gastrointestinal angiodysplasia at an alarming rate. It has been speculated that LVAD support itself may cause angiodysplasia. The relationship to abnormal vWF metabolism is unknown. We tested the hypothesis that abnormal gastrointestinal vascularity develops during continuous-flow LVAD support.
Small bowel was obtained from deceased humans, cows, and sheep supported with a continuous-flow LVAD (n=9 LVAD, n=11 control). Transmural sections of jejunum were stained with fluorescein isothiocyanate-conjugated isolectin-B4 for endothelium to demarcate vascular structures and quantify intestinal vascularity. Paired plasma samples were obtained from humans before LVAD implantation and during LVAD support (n=41). vWF multimers and degradation fragments were quantified with agarose and polyacrylamide gel electrophoresis and immunoblotting. Abnormal vascular architecture was observed in the submucosa of the jejunum of human patients, cows, and sheep supported with a continuous-flow LVAD. Intestinal vascularity was significantly higher after LVAD support versus controls (5.2±1.0% versus 2.1±0.4%, =0.004). LVAD support caused significant degradation of high-molecular-weight vWF multimers (-9±1%, <0.0001) and accumulation of low-molecular-weight vWF multimers (+40±5%, <0.0001) and vWF degradation fragments (+53±6%, <0.0001).
Abnormal intestinal vascular architecture and LVAD-associated vWF degradation were consistent findings in multiple species supported with a continuous-flow LVAD. These are the first direct evidence that LVAD support causes gastrointestinal angiodysplasia. Pathologic vWF metabolism may be a mechanistic link between LVAD support, abnormal angiogenesis, gastrointestinal angiodysplasia, and bleeding.
本尸检研究旨在确定胃肠道血管扩张症是否在连续血流左心室辅助装置(LVAD)支持期间发生。
LVAD 支持会导致 von Willebrand 因子(vWF)病理性降解,并以惊人的速度导致胃肠道血管扩张症出血。有人推测 LVAD 支持本身可能导致血管扩张症。与异常 vWF 代谢的关系尚不清楚。我们检验了这样一个假设,即在连续血流 LVAD 支持期间会出现异常的胃肠道血管生成。
从小肠获得了来自接受连续血流 LVAD 支持的已故人类、牛和绵羊(n=9 LVAD,n=11 对照组)。用荧光素异硫氰酸酯结合的异硫氰酸荧光素-B4 对空肠的壁层进行染色,以标记血管结构并定量肠道血管生成。从人类患者在 LVAD 植入前和支持期间获得配对的血浆样本(n=41)。用琼脂糖和聚丙烯酰胺凝胶电泳和免疫印迹法对 vWF 多聚体和降解片段进行定量。在接受连续血流 LVAD 支持的人类、牛和绵羊的空肠黏膜下层观察到异常的血管结构。与对照组相比,LVAD 支持后肠道血管生成明显增加(5.2±1.0%对 2.1±0.4%,=0.004)。LVAD 支持导致高分子量 vWF 多聚体显著降解(-9±1%,<0.0001),低分子量 vWF 多聚体积聚(+40±5%,<0.0001)和 vWF 降解片段(+53±6%,<0.0001)。
在接受连续血流 LVAD 支持的多种物种中,异常的肠道血管结构和与 LVAD 相关的 vWF 降解是一致的发现。这些是 LVAD 支持导致胃肠道血管扩张症的第一个直接证据。病理性 vWF 代谢可能是 LVAD 支持、异常血管生成、胃肠道血管扩张症和出血之间的机制联系。